BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
Italy Fines Apple €98.6 Million Over App Store Dominance 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
HEIDELBERG, Germany, Feb. 4, 2016 -- Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, announced today that Dr. Adi Hoess, CEO, will present at the Leerink Partners 5th Annual Global Healthcare Conference on Thursday, February 11, 2016 at 11:10 a.m. (ET) in New York City.
To access a simultaneous webcast of Dr. Hoess' presentation online, log on to http://wsw.com/webcast/leerink26/afmd or go to the "Events" section on the "Media" page of the Affimed website at http://www.affimed.com/events.php. A replay of the webcast will be available from Affimed's website for 30 days following the conference. Dr. Hoess' presentation will be available for download in PDF format immediately following the conference presentation in the "Events" section of the Media page of Affimed's website at http://www.affimed.com/events.php.
About Affimed N.V.
Affimed (Nasdaq: AFMD) is a clinical-stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies. Affimed's product candidates are being developed in the field of immuno-oncology, which represents an innovative approach to cancer treatment that seeks to harness the body's own immune defenses to fight tumor cells. The most potent cells of the human defense arsenal are types of white blood cells called natural killer cells, or NK-cells, and T-cells. Affimed's proprietary, next-generation bispecific antibodies, called TandAbs for their tandem antibody structure, are designed to direct and establish a bridge between either NK-cells or T-cells and cancer cells, triggering a signal cascade that leads to the destruction of cancer cells. Affimed has focused its research and development efforts on three proprietary TandAb programs for which it retains global commercial rights. For more information, please visit www.affimed.com.
IR Contact:
Caroline Stewart, Head of IR
Phone: +1 347394 6793
E-Mail: [email protected] or [email protected]
Media Contact:
Anca Alexandru, Head of Communications
Phone: +49 6221 64793341
E-Mail: [email protected]
